Biomea Fusion 2025 Financial Report

[ad_1] BMEA|EPS -$1.18|Net Loss $61.8M Company Overview Biomea Fusion is a clinical-stage company developing oral small molecule therapies targeted at treating diabetes and obesity. Key Financial Figures For the year ended December 31, 2025, Biomea reported an EPS (net loss…